Crossject engage Syneos Health pour le lancement commercial du ZEPIZURE® aux États-Unis
January 04, 2024 12:00 ET
|
CROSSJECT
Communiqué de presse Crossject engage Syneos Health pour le lancement commercial du ZEPIZURE® aux États-Unis Crossject élargit ses activités d'accès au marché dans le cadre des...
Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®
January 04, 2024 12:00 ET
|
CROSSJECT
Press Release Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE® Crossject expanding market access activities in preparation for filing for marketing authorization ...
Crossject reports financial results and business highlights for first half of 2023
September 26, 2023 11:35 ET
|
CROSSJECT
Press Release Crossject reports financial results and business highlights for first half of 2023 Strong progress in bringing drugs for use in emergency situations towards the market ...
Crossject présente ses résultats financiers et faits marquants du premier semestre 2023
September 26, 2023 11:35 ET
|
CROSSJECT
Communiqué de presse Crossject présente ses résultats financiers et faits marquants du premier semestre 2023 De solides avancées vers la mise sur le marché de médicaments dédiés aux situations...
Injectable Drug Delivery Market is anticipated to reach beyond US$ 101.2 Billion by the end of 2033, Persistence Market Research
March 22, 2023 09:35 ET
|
Persistence Market Research
New York, March 22, 2023 (GLOBE NEWSWIRE) -- The Injectable Drug Delivery Market was about US$ 41.5 Billion in 2022 to US$ 101.2 Billion by 2033, With at a CAGR of 8.4%. Injectable drug delivery...